BUZZ-Leerink downgrades Bristol-Myers Squibb rating, citing risks in the R&D pipeline
路透社2026/10/05 12:56October 5th - ** Bristol-Myers Squibb (BMY.N) shares fell 1.9% to $60 in pre-market trading ** ** Leerink Partners downgraded the pharmaceutical company's stock rating from “Outperform” to “Market Perform” and lowered its target price from $73 to $59 ** ** As of the previous trading session's close, BMY had risen 13.4% year to date; the new target price implies about 3.5% downside ** ** The brokerage highlighted uncertainty around three key projects for BMY and noted approaching patent expirations ** ** Leerink warned that the experimental pulmonary drug admilparant may disappoint in terms of efficacy and safety, citing possible liver issues and low blood pressure; it cut 2032 sales forecast by 38% ** ** They questioned whether experimental anticoagulant milvexian can rival Bristol-Myers Squibb’s Eliquis in preventing strokes in patients with atrial fibrillation, and lowered 2032 sales forecast by 25% ** ** Even if the antipsychotic drug Cobenfy is approved for treating Alzheimer’s-related psychosis, demand may still be limited by the availability of lower-priced generic antipsychotics ** ** EPS forecast for 2032 was cut by 11% to $4.96 (For non-native speakers’ convenience, Reuters automatically translates articles into multiple languages; Reuters makes no guarantee of accuracy due to possible automated translation errors or lack of context, and accepts no liability for any damages caused by use of the machine translation. The machine-translated text is provided solely for reader convenience.)
October 5 - ** Bristol Myers Squibb (BMY.N) shares fell 1.9% in pre-market trading, at $60
** Leerink Partners downgraded the pharmaceutical company's stock rating from "Outperform" to "Market Perform" and lowered the target price from $73 to $59
** As of the previous trading session's close, BMY had risen 13.4% so far this year; the new target price suggests the stock has about 3.5% downside potential
** The brokerage noted uncertainty in three of BMY's key projects, and the company is about to face patent expirations
** It said the experimental lung drug admilparant may disappoint in terms of efficacy and safety, including potentially causing liver issues and low blood pressure; 2032 sales forecast lowered by 38%
** Questioned whether the experimental anticoagulant milvexian can rival Bristol Myers Squibb's Eliquis in preventing strokes in patients with arrhythmia; 2032 sales forecast cut by 25%
** Pointed out that even if the antipsychotic drug Cobenfy is approved to treat Alzheimer’s-related psychosis, demand could remain limited due to lower-priced generic antipsychotics
** Lowered 2032 earnings per share (EPS) forecast by 11% to $4.96
(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translations, which are provided solely for readers' convenience. Reuters assumes no liability for any harm or loss caused by the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nymex US crude oil futures main contract breaks above $90 per barrel
The main Nymex US crude oil futures contract has just surpassed the $90.00 per barrel mark, now quoted at $90.01 per barrel, up 0.64% on the day.
Hot Review: Market Confusion Intensifies, IEA to Finalize Diesel Reserve Release Details Next Week
(1) The G7 agreed last week to release 100 million barrels of reserves, and the IEA Council is expected to discuss details of the reserve release on October 14-15. (2) The EU's Oil Coordination Group will meet on Wednesday to determine the EU's position. According to sources, Western energy watchdog agencies will meet next week to finalize details regarding the release of diesel reserves. The market is becoming increasingly confused, as it remains unclear how much inventory Europe and the US plan to release to alleviate supply shortages and record-high prices. (3) A source said that G7 member Italy will participate in this reserve release. A spokesperson for the European Commission stated on Tuesday that the EU Oil Coordination Group will meet on Wednesday. The White House did not immediately respond to a request for clarification on the details of this reserve release.
BHP evaluates options for disposal of Western Australia nickel assets, decision expected by February 2027
Sources report that BHP (BHP.US) is evaluating multiple options for divesting its Western Australia nickel assets, including an asset spin-off sale. The related operations remain temporarily suspended, and the company expects to complete this strategic review by February 2027.
Apple (AAPL.US) reportedly partners with LG to enter the smart home market: doorbells, thermostats, cameras, and other accessories will carry the LG brand
According to sources cited by Zhitong Finance APP, Apple (AAPL.US) is set to expand its lineup of smart home devices, including doorbells, thermostats, and other accessories, through an unusual partnership with LG Electronics. These products will be incorporated into an ecosystem of devices that work seamlessly with Apple's new smart home hub and will also be compatible with the upgraded HomePod mini and new TV set-top box. Apple's new in-house devices are scheduled to be launched on October 13.
